drugset / Trial / NCT03890003

A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes

NCT03890003

Completed 10 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelDevice feasibility

Summary

The purpose of this early feasibility study is to assess the predictive low glucose suspend (PLGS) feature's safety, functionality and performance.

Timeline

Start
2019-03-28
Primary completion
2019-05-06
Completion
2019-05-06

Drugs

EvaluationDrugModalityDoseRoute
Background Insulin Lispro Protein / enzyme biologic Subcutaneous